[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Wintrust Financial Corp (WTFC) – Insider Form 4 Filing

Director Marla F. Glabe reported the acquisition of 428 shares of Wintrust Financial common stock on 30 June 2025 under the shareholder-approved Director’s Deferred Fee & Stock Plan. The transaction is coded “A” (open-market or plan acquisition) at an indicated reference price of $112.46 per share, implying a dollar value of roughly $48,100. Following the purchase, Glabe’s direct beneficial ownership rises to 22,197 shares.

• No derivative securities were transacted.
• The filing is made by a single reporting person and bears an attorney-in-fact signature dated 2 July 2025.
• The acquisition represents about 1.9% incremental ownership relative to Glabe’s revised holdings.

While modest in size relative to WTFC’s average trading volume and market capitalization, director share accumulation can be viewed as a marginally constructive signal of insider confidence.

Positive

• Director increased personal holdings, a traditional—albeit modest—signal of insider confidence.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small director buy (~$48k) marginally positive, but immaterial to WTFC fundamentals.

The Form 4 shows Director Marla F. Glabe adding 428 shares via the company’s deferred fee stock plan. The purchase lifts her stake to 22,197 shares, worth roughly $2.5 million at current prices. Although insider acquisitions often indicate conviction, the size (<0.01% of WTFC’s outstanding shares) limits market impact. The transaction is routine compensation-related, carries no strategic implications, and does not alter the investment thesis for Wintrust Financial. Overall, I view the filing as neutral from a valuation or earnings-forecast standpoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Theagene Jean-Manasse

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.8	06/30/2025		A		20,380		06/30/2025(1)	06/30/2035	Common Stock	20,380	$0	20,380	D

Explanation of Responses:

1. The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Jean-Manasse Theagene	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Director Marla F. Glabe purchase according to the WTFC Form 4?

She acquired 428 shares of Wintrust Financial common stock on 06/30/2025.

At what price were the WTFC shares recorded in the Form 4?

The filing references a price of $112.46 per share.

How many Wintrust Financial shares does Glabe own after the transaction?

Her direct beneficial ownership stands at 22,197 shares.

Was any derivative security activity reported in this Form 4?

No; there were no options, warrants, or other derivatives reported.

Is the insider transaction large enough to affect WTFC’s share count?

No; 428 shares is immaterial relative to Wintrust’s total shares outstanding.